ASX Announcement - FY26 Full Year Results
Released
Released
Announcement PDF
PolyNovo Limited (ASX: PNV) ABN 96 083 866 862
2/320 Lorimer Street, Port Melbourne, Victoria 3207 Australia
+61 3 8681 4050 [email protected]
investors.polynovo.com
26 August 2026
ASX Announcement
PolyNovo 2026 Full Year Financial Results
PolyNovo Limited (“PolyNovo”, the “Company” or “we”), a leading medical technology company transforming
the management of complex wounds, today announces its financial results for the year ended 30 June 2026, its
Appendix 4E and accompanying investor presentation. All figures are in AUD unless otherwise stated.
FY26 Highlights
• Commercial sales increased 16.7% to $138.4m (21.3% in constant currency)
• Total revenue increased 16.1% to $150.0m
• Positive EBITDA of $12.1m
• Positive NPAT of $7.3m
• Operating cash flow of $23.1m and free cash flow of $9.4m, reflecting increased profitability and
improved working capital management
• Manufacturing output increased significantly in the second half, supporting improved operational
efficiency and future growth capacity
• Construction of PolyNovo's new manufacturing facility was completed, with validation activities
progressing ahead of planned transition in FY27
• Continued expansion of clinical evidence supporting NovoSorb® applications beyond burns, including
completion of key BARDA-supported clinical trial milestones
• NovoSorb® MTX commercial rollout progressed, validating the broader potential of the NovoSorb®
platform
• PMA submission activities advanced, supporting future reimbursement and market expansion
opportunities in the United States
Summary of Group Results
$m FY26 FY25 Change (%)
Total revenue (including interest and other
income)
150.0 129.2 16.1%
Commercial sales 138.4 118.6 16.7%
Changes in inventories of finished goods and
work in progress
(15.2) (5.2) 193.1%
Gross margin 89.0% 95.6% (6.9%)
Research and development (including clinical
expenses)
(5.3) (8.5) (36.9%)
EBITDA 12.1 11.2 8.1%
NPAT 7.3 13.2 (44.4%)
PolyNovo generated total revenue of $150.0m in FY26, an increase of 16.1% compared to FY25. Commercial
sales increased 16.7% to $138.4m, and on a constant currency basis, increased 21.3%.
2
Gross margin was 89.0%, compared with 95.6% in the prior period. The reduction reflects changes in
inventories of finished goods. Despite these impacts, underlying manufacturing performance improved
materially during the second half as production volumes increased to normal levels.
Research and development expenditure, including clinical activities decreased with the reduction primarily
associated with the completion of BARDA-pivotal clinical trial activities.
Employee-related costs slightly increased and headcount remained steady at circa 300 employees, while
corporate and administrative expenses remained broadly stable despite the Company's expanding global
footprint.
EBITDA increased 8.1% to $12.1 million from $11.2 million in the prior period. Underlying EBITDA was $13.4m,
up 50.4% on the prior period of $8.9m, demonstrating revenue growth and disciplined management of
operating expenditure. Net profit after tax was $7.3m, and while lower than the prior year, reflects non-recurring
impacts such as the R&D Innovation Centre fire, which was offset by insurance recoveries. Furthermore, a tax
benefit of $5.7m was recorded in FY25, whereas a tax expense of $0.5m was recorded in FY26.
Regional Performance
Growth was delivered across all regions, with particularly strong performance in APAC and continued
momentum across direct markets. Distributor-supported markets also contributed to overall growth.
Region FY26 ($m) FY25 ($m) Change (%)
Change (%)
constant currency
Americas 104.1 90.8 14.7% 20.2%
EMEA 20.6 17.6 17.3% 17.6%
APAC 13.7 10.2 33.6% 37.8%
Total 138.4 118.6 16.7% 21.3%
Commentary
Bruce Peatey, Chief Executive Officer of PolyNovo said: “FY26 was a year of capability building and strategic
alignment. We delivered strong commercial growth, expanded our manufacturing capacity, strengthened our
balance sheet and continued to invest in the evidence, products and capabilities that will drive PolyNovo's next
phase of growth. During FY26, we sharpened our strategic focus and aligned the business around three clear
priorities: accelerating growth in our core wound care franchise, building the next growth engine for PolyNovo,
and establishing the global operating structure required to scale efficiently and consistently. Importantly, we
achieved this while generating strong cash flow, strengthening our balance sheet, and continuing to invest in
the future of the NovoSorb platform.
The planned PMA submission is an important milestone in PolyNovo's U.S. growth strategy. Successful
approval has the potential to provide a pathway to expanded access and support broader adoption of
NovoSorb®. While burns remains an important foundation for the business, our opportunity extends well
beyond. Growth in indications outside burns in the U.S. has delivered a CAGR of 52.8% over the past three
years and continues to represent one of the most significant drivers of future value creation.
The clinical evidence supporting NovoSorb® continues to expand, with significant published evidence now
generated outside burns. Clinicians have always guided our approach to product development and
enhancements, and the team and I are confident that growth momentum can be strengthened as we go deeper
into existing accounts, deliver the evidence underpinning further indication expansion, and make NovoSorb®
MTX available more broadly, including in new geographies.
3
With NovoSorb® MTX gaining increased traction, we have commercial validation of the broader potential of the
platform. But there is much more that we can do with NovoSorb® technology, and our new Chief Scientific
Officer Dr Marthe D‘Ombrain will lead our efforts in this space. In FY27 we will establish a dedicated business
development function, with a remit to identify and progress strategic opportunities to extend the NovoSorb®
platform, including potential partnerships, licensing and other complementary growth opportunities.
Our focus in FY27 is execution. We have a growing core franchise, increasing adoption of NovoSorb® MTX,
significant opportunity in complex wounds, and a clearly defined set of regulatory, commercial and innovation
priorities. Our task now is to translate those strengths into sustained growth and increasing operating leverage.”
FY26 Results Presentation
The FY26 results presentation will be live streamed today at 10.30 am Australian Eastern Standard Time. To
access the webcast, shareholders will need to register prior to the commencement of the presentation.
To register
• Visit https://event.choruscall.com/mediaframe/webcast.html?webcastid=JWUI5g03
• Once registered, attendees will receive a confirmation email with additional information about the
event.
To read PolyNovo’s Appendix 4E and accompanying investor presentation visit investors.polynovo.com
This announcement has been authorised by the PolyNovo Board of Directors.
Further information:
Amy Demediuk, General Counsel & Company Secretary
Mobile: + 61 419 858 691
Email: [email protected]
Media contact:
[email protected]
About PolyNovo®
PolyNovo (ASX: PNV) is a leading medical technology company transforming the management of complex
wounds. Headquartered in Melbourne, Australia, it has international operations in the United States, United Kingdom,
India, Hong Kong and Singapore and several other markets supported by distributor partners.
The proprietary NovoSorb®
polymer is addressing significant unmet needs in wound care, as evidenced by its clinical
adoption and patient outcomes, and the Company is leveraging the technology platform to develop new products and
markets.
Achievements to date, including continued revenue growth, profitability, numerous clearances and registrations, as well
as market leadership in several geographies, provide a strong foundation for continued growth.
For more information see polynovo.com
View this announcement on PolyNovo’s investor hub
Share your feedback
Discover